Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enh...

Full description

Bibliographic Details
Main Authors: Choi, Catherine H., Schoenfeld, Brian P., Bell, Aaron J., Hinchey, Paul, Kollaros, Maria, Gertner, Michael J., Woo, Newton H., Tranfaglia, Michael R., Zukin, R. Suzanne, McDonald, Thomas V., Jongens, Thomas A., McBride, Sean M.J., Bear, Mark
Other Authors: Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Format: Article
Language:en_US
Published: Elsevier 2016
Online Access:http://hdl.handle.net/1721.1/102243

Internet

http://hdl.handle.net/1721.1/102243

Similar Items